Update Your Colistin and Polymyxin B Protocols
You'll see more focus on optimizing polymyxin antibiotics...due to new guidelines from the Infectious Diseases Society of America and others.
IV colistin (polymyxin E) and polymyxin B have been around for decades. But nephrotoxicity concerns limit their use.
Now we're reaching for polymyxins more often due to increases in multidrug-resistant (MDR) gram-negative organisms, such as carbapenem-resistant Enterobacteriaceae or some Pseudomonas or Acinetobacter.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote